Opdivo

Give as IV infusion over 30mins. ≥18yrs (as single-agent or in combination with cabozantinib): 240mg every 2 weeks or 480mg every 4 weeks, until disease progression or unacceptable toxicity. In combination with cisplatin/gemcitabine (given on same day): 360mg every 3 weeks for up to 6 cycles, then followed by 240mg every 2 weeks or 480mg every 4 weeks as single agent, until disease progression, unacceptable toxicity, or up to 2 years from first dose. In combination with ipilimumab: 3mg/kg (followed by ipilimumab on the same day) every 3 weeks for 4 doses, then followed by 240mg every 2 weeks or 480mg every 4 weeks as single agent, until disease progression, unacceptable toxicity, or up to 2yrs. Adjuvant: 240mg every 2 weeks or 480mg every 4 weeks, until disease recurrence or unacceptable toxicity for up to 1 year. Dose modifications: see full labeling.

Give as IV infusion over 30mins. For CRC, HCC: Continue until disease progression or unacceptable toxicity. CRC: ≥12yrs: Single agent (≥40kg): 240mg every 2 weeks or 480mg every 4 weeks; (<40kg): 3mg/kg every 2 weeks; combination therapy (with ipilimumab): 3mg/kg (followed by ipilimumab on the same day) every 3 weeks for 4 doses, then followed by 240mg every 2 weeks or 480mg every 4 weeks (if ≥40kg) or 3mg/kg every 2 weeks (if <40kg) as single agent. HCC (with ipilimumab): ≥18yrs: 1mg/kg (followed by ipilimumab on the same day) every 3 weeks for 4 doses, then followed by 240mg every 2 weeks or 480mg every 4 weeks as single agent. Resected esophageal or GEJC: ≥18yrs: 240mg every 2 weeks or 480mg every 4 weeks, until disease progression or unacceptable toxicity for up to 1 year. ESCC: ≥18yrs: Single agent: 240mg every 2 weeks or 480mg every 4 weeks, until disease progression or unacceptable toxicity. First-line combination therapy (with fluoropyrimidine- and platinum-containing chemotherapy): 240mg every 2 weeks or 480mg every 4 weeks (followed by fluoropyrimidine- and platinum-containing chemotherapy on the same day); (with ipilimumab): 3mg/kg every 2 weeks or 360mg every 3 weeks (followed by ipilimumab on the same day). Both combinations: continue until disease progression, unacceptable toxicity, or up to 2 years. GC, GEJC, EAC (with fluoropyrimidine- and platinum-containing chemotherapy on the same day): ≥18yrs: 240mg every 2 weeks or 360mg every 3 weeks until disease progression, unacceptable toxicity, or up to 2 years. Dose modifications: see full labeling.

Give as IV infusion over 30mins. ≥18yrs: 240mg every 2 weeks or 480mg every 4 weeks, until disease progression or unacceptable toxicity. Dose modifications: see full labeling.

Give as IV infusion over 30mins. ≥18yrs: 240mg every 2 weeks or 480mg every 4 weeks, until disease progression or unacceptable toxicity. Dose modifications: see full labeling.

Give as an IV infusion over 30mins. ≥12yrs: (≥40kg): 240mg every 2 weeks or 480mg every 4 weeks; (<40kg): 3mg/kg every 2 weeks or 6mg/kg every 4 weeks. As a single agent (for unresectable or metastatic melanoma): continue until disease progression or unacceptable toxicity; (for adjuvant treatment): continue until disease recurrence or unacceptable toxicity for up to 1 year. In combination with ipilimumab: 1mg/kg (followed by ipilimumab on the same day) every 3 weeks for 4 doses, then followed by 240mg every 2 weeks or 480mg every 4 weeks (if ≥40kg) or 3mg/kg every 2 weeks or 6mg/kg every 4 weeks (if <40kg) as a single agent until disease progression or unacceptable toxicity. Dose modifications: see full labeling.

Give as IV infusion over 30mins. ≥18yrs: Neoadjuvant of resectable NSCLC: 360mg every 3 weeks with platinum-doublet chemotherapy (on the same day) every 3 weeks for 3 cycles. Metastatic NSCLC with PD-L1: 360mg every 3 weeks (with ipilimumab 1mg/kg every 6 weeks), continue with ipilimumab until disease progression, unacceptable toxicity, or up to 2 years in patients without disease progression. Metastatic or recurrent NSCLC: 360mg every 3 weeks (with ipilimumab 1mg/kg every 6 weeks) and histology-based platinum-doublet chemotherapy every 3 weeks (for 2 cycles only), continue with ipilimumab until disease progression, unacceptable toxicity, or up to 2 years in patients without disease progression. Metastatic NSCLC (single-agent): 240mg every 2 weeks or 480mg every 4 weeks, until disease progression or unacceptable toxicity. Mesothelioma: 360mg every 3 weeks (with ipilimumab 1mg/kg every 6 weeks), continue with ipilimumab until disease progression, unacceptable toxicity, or up to 2 years in patients without disease progression. In combination therapies with other agents: administer Opdivo first followed by ipilimumab, and/or platinum-doublet chemotherapy on the same day. Dose modifications: see full labeling.